Analyzing Impact of Comorbidities on Mortality in SARC-CoV-2 Positive Patients and Prediction Modeling Based on Retrospective Cohort Study for Mexico

  • Narayana Darapaneni, Neeraj Rajput, Satinder Pal Singh, Akash Wadhwa, Chetan Kathooria ,Anwesh Reddy Paduri


This epidemiologic study includes all clinically suspected, and laboratory-confirmed cases nationwide. The objective of this study was to analyze the impact of comorbidities like obesity, diabetes and hypertension along with the age on the Case Fatality Rate (CFR) and the development of adverse events in patients positive for severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) in the Mexican population.

We analyzed the data available from General Directorate of Epidemiology of the Mexican Ministry of Health, for 629,176 patients who were tested for SARS-CoV-2 since the beginning of the outbreak to July 02, 2020. We investigated the risk of death and the development of the adverse events (hospitalization, pneumonia, intubation and intensive care unit (ICU) admission) based on the number of comorbidities and age of each patient. The total number of tested patients 43.14% were tested COVID-19 (+)ve. 30% (+)ve were admitted to the hospital, 23.12% developed pneumonia (14.12% hospitalized), 13.91% used either ICU or ventilator support and total CFR was 12.55%. In the ICU and Ventilator support, there are approx. 70% people who have 1 or more comorbidities specially Diabetes, Hypertension and Obesity. The comorbidities are strongly contributing to the CFR where more than 72% patient have at least 1 or more comorbidity. Age when combined with other comorbidities, is another major factor contributing to the high ICU & Ventilator requirement and mortality rate.